Levothyroxine Sodium

左甲状腺素钠

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLevothyroxine Sodium
Drug Alias Namelevotiroxina de sodio左旋甲状腺素钠levothyroxinum natricum优甲乐雷替斯 +[19
ClassificationSmall molecules
Mechanisms of ActionThyroid hormone receptor agonists
TargetsThyroid hormone receptor
Therapy Area/IndicationsMyxedema comaSchizophreniaBipolar Disorder +[22
Global Approved IndicationsHypothyroidismHyperthyroidismThyroid Neoplasms
Approved Indications in ChinaHypothyroidismHyperthyroidismThyroid Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2000/01/01
Country/TerritoryBelgiumCanadaUnited States +[12
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active IndicationsMyxedema comaSchizophreniaDelayed Emergence from Anesthesia +[15
Inactive IndicationsBipolar DisorderPostoperative ComplicationsDyslipidemias +[7

Other Information

ATC CodeH03AA01